Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study.
The standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC) is EGFR tyrosine kinase inhibitors. However, concurrent mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma and combination therapies may offer a superior approach.
The standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC) is EGFR tyrosine kinase inhibitors. However, concurrent mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma and combination therapies may offer a superior approach.
What the study was
- Study design
- Cohort/Observational Study
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Oncologist
Why it surfaced
Matched watchlist topic 'Early cancer detection (liquid biopsy, ctDNA, cfDNA)'. Study design: Cohort/Observational Study. Score: 8/10 (N:2, R:3, D:1, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.